Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
ORAGENICS PROVIDES INVESTOR UPDATE
ORAGENICS PROVIDES INVESTOR UPDATE
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Rises By 39.0%
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Oragenics (NYSEAMERICAN:OGEN) Trading Down 0.3% – Here’s Why
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
Oragenics Q3 2025 Shareholder Update
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
Oragenics Q2 2025 Shareholder Update
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
Oragenics Completes Approximately $16.5 Million Offering
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Announces Pricing of Public Offering
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Announces Pricing of Public Offering
Oragenics, Inc. Announces Proposed Public Offering
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer